AbbVie lifts 2026 neuroscience outlook to Alpha Vantage · TradingView · · AI-summarised by FinFlash
AbbVie's neuroscience segment generated $3.39 billion in third-quarter revenue, up 19.5% year over year, driven by Vraylar, Ubrelvy, Qulipta and Botox Therapeutic. The company raised its 2026 neuroscience sales outlook to Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.
Alpha Vantage · TradingView · · AI-summarised by FinFlash
AbbVie's neuroscience segment generated $3.39 billion in third-quarter revenue, up 19.5% year over year, driven by Vraylar, Ubrelvy, Qulipta and Botox Therapeutic. The company raised its 2026 neuroscience sales outlook to Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.Understand the context